| Patients N = 203 |
---|---|
Female | 96 (47.3%) |
Median age (IQ range) | 1.8 (0.7 – 4) years |
CDC Clinical Class | Â |
   N | 2 (0.9%) |
   A | 17 (8.4%) |
   B | 138 (68%) |
   C | 46 (22.7%) |
CDC Immunological | Â |
   1 | 44 (22%) |
   2 | 85 (42.5%) |
   3 | 71 (35.5%) |
CD4 percentage | 19 (14 – 26) |
Hospitalization | Â |
   None in past | 52 (25.6%) |
   1 | 54 (26.6%) |
   2 | 53 (26.11%) |
   3 | 28 (13.79%) |
   4 | 11 (5.42%) |
   5 | 5 (2.46%) |
Recruited to study during or immediately after current hospitalization | 91 (44.8%) |
No hospitalization | 38 (18.7%) |
TMP-SMX status | Â |
   No previous experience | 47 (23.3%) |
   On drug at baseline | 141 (69.8) |
   History of exposure | 15 (7.4%) |
Median weight for age Z-score (IQ range) | -1.6 (-3 – -0.4) |
Antiretroviral therapy at baseline | 19 (9.4%) |
   Time on therapy | 0.5 (0.2 – 1.1) years |
Died within 12 months of enrolment | 35 (17.2%) |